review Open AccessTop 1% cited

Pharmacological inhibitors of glycogen synthase kinase 3

Trends in Pharmacological Sciences · 2004 · Vol. 25(9) · pp. 471–480

Laurent Meijer✉(Station Biologique de Roscoff)M FLAJOLET(Rockefeller University)Paul Greengard(Rockefeller University)

Wnt/β-catenin signaling in development and cancer Cancer-related gene regulation Cancer-related Molecular PathwaysGSK-3Glycogen synthaseGSK3BNeurosciencePharmacologyMedicineBiochemistryChemistryEnzymeKinase

MeSH terms

AnimalsCell DifferentiationDiabetes Mellitus, Type 2Enzyme InhibitorsHumansNeoplasmsNervous System DiseasesParasitic DiseasesStem CellsStructure-Activity RelationshipSignal TransductionGlycogen Synthase Kinase 3

Citations

576

FWCI

13.57

field-weighted impact

References

Percentile

99%

vs. same field & year

Citations per year

Cited by

Recent advances in the synthesis of (hetero)aryl-substituted heteroarenes via transition metal-catalysed direct (hetero)arylation of heteroarene C–H bonds with aryl halides or pseudohalides, diaryliodonium salts, and potassium aryltrifluoroborates

Tetrahedron · 2009 · 556 citations

References

GSK3 takes centre stage more than 20 years after its discovery

Biochemical Journal · 2001 · 1,294 citations

GSK-3: tricks of the trade for a multi-tasking kinase

Journal of Cell Science · 2003 · 2,066 citations

The specificities of protein kinase inhibitors: an update

Biochemical Journal · 2003 · 1,355 citations

Specificity and mechanism of action of some commonly used protein kinase inhibitors

Biochemical Journal · 2000 · 4,060 citations

The glamour and gloom of glycogen synthase kinase-3

Trends in Biochemical Sciences · 2004 · 1,510 citations

Protein kinases — the major drug targets of the twenty-first century?

Nature Reviews Drug Discovery · 2002 · 2,171 citations

Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.